BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7577621)

  • 21. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
    Diccianni MB; Chau LS; Batova A; Vu TQ; Yu AL
    Cancer Lett; 1996 Jul; 104(2):183-92. PubMed ID: 8665486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
    Southgate J; Proffitt J; Roberts P; Smith B; Selby P
    Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
    Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
    Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
    Zariwala M; Liu E; Xiong Y
    Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
    Zariwala M; Xiong Y
    Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
    Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
    J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
    Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features.
    Ohnishi H; Guo SX; Ida K; Taki T; Naritaka S; Bessho F; Yanagisawa M; Hanada R; Eguchi M; Kamada N; Kita K; Yamamori S; Hayashi Y
    Leukemia; 1997 Dec; 11(12):2120-4. PubMed ID: 9447829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
    Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
    Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.
    Aguiar RC; Sill H; Goldman JM; Cross NC
    Leukemia; 1997 Feb; 11(2):233-8. PubMed ID: 9009086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.
    Chim CS; Wong AS; Kwong YL
    Ann Hematol; 2003 Dec; 82(12):738-42. PubMed ID: 14513284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.
    Omura-Minamisawa M; Diccianni MB; Batova A; Chang RC; Bridgeman LJ; Yu J; Pullen J; Bowman WP; Yu AL
    Clin Cancer Res; 2000 Apr; 6(4):1219-28. PubMed ID: 10778944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of p18 mutations or deletions in lymphoid malignancies.
    Otsuki T; Jaffe ES; Wellmann A; Kumar S; Condron KS; Raffeld M
    Leukemia; 1996 Feb; 10(2):356-60. PubMed ID: 8637248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
    Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level.
    Jamal R; Thomas NS; Gale RE; Linch DC
    Leukemia; 1996 Apr; 10(4):629-36. PubMed ID: 8618439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.
    Kawamata N; Seriu T; Koeffler HP; Bartram CR
    Cancer; 1996 Feb; 77(3):570-5. PubMed ID: 8630967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
    Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
    Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.